期刊文献+

内皮抑素及其介入法应用 被引量:1

Endostatin and its interventional application
下载PDF
导出
摘要 血管生成涉及机体的许多生理和病理活动,包括肿瘤的发生、维持和进展。血管生成的具体情况取决于促血管生成因子与抗血管生成因子之间的动态平衡。血管生成抑制剂可特异性抑制内皮细胞增殖、迁移和管道形成,其中之一是内皮抑素。内皮抑素具有强烈的抑制血管生成作用,作用范围广,对多血管肿瘤有治疗作用。本文根据内皮抑素的作用机制、结构和生物学功能,推荐抗肿瘤治疗的具体方法和产品,指出其在介入放射学领域中应用时需注意的问题。科研和临床工作中必须认真设计科学、严格的使用方案。只有与有效破坏肿瘤组织的方法联合应用,争取协同、加强作用,才能得到显著的客观疗效。 Angiogenesis, i.e. neovascularization from preexisting vasculature, is involved in a variety of physiological and pathological processes of the body, including the initiation, maintenance and progression of tumors. The process of angiogenesis depends on the dynamic balance between the activities of pro- angiogenic and anti-angiogenic factors. Angiogenesis inhibitors specifically prevent endothelial cells from proliferation, migration and tube formation. One of the inhibitors is endostatin, which is of wide spectrum and possesses profound angiogenesis inhibition and therapeutic effects on tumors with rich vasculature. This paper aims to explain the mechanism of the action, structure and biological function of endostatin, and to discuss its application in. anti-neoplastic therapies and the issues in the field of interventional radiology. The authors point out emphatically that the application scheme must be designed strictly and scientifically. Only when combination use of endostatin with other therapeutics which can effectively destroy tumor tissues is carried out to gain synergistic and intensified effect, can marked objective efficacy he obtained.
出处 《介入放射学杂志》 CSCD 北大核心 2009年第4期241-243,共3页 Journal of Interventional Radiology
关键词 血管生成 内皮抑素 肿瘤 治疗 介入给药 angiogenesis endostatin tumor therapy interventional administration
  • 相关文献

参考文献17

  • 1O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: endogenous inhibitor of angiogenesis and tumor growth[J]. Cell, 1997, 88: 277- 285.
  • 2Dell'Eva R, Pfeffer U, Indraccolo S, et al. Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy[J]. Endothelium, 2002, 9: 3- 10.
  • 3Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies for malignant gliomas [J]. Lancet Neurol, 2008, 7: 1152 - 1160.
  • 4Sato Y. Update on endogenous inhibitors of angiogenesis [J]. Endothelium, 2006, 13: 147- 155.
  • 5Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis [J]. Cancer Res, 2005, 65 : 3967 - 3979.
  • 6Zatterstrom UK, Felbor U, Fukai N, et al. Collagen ⅩⅧ/ endostatin structure and functional role in angiogenesis [J]. Cell Struct Funct, 2000, 25:97 - 101.
  • 7Digtyar AV, Pozdnyakova NV, Feldman NB, et al. Endostatin: current concepts about its biological role and mechanisms of action[J]. Biochemistry, 2007, 72: 235- 246.
  • 8Neskey DM, Ambesi A, Pumiglia KM, et al. Endostatin and anasteUin inhibit distinct aspects of the angiogenic process[J]. J Exp Clin Cancer Res, 2008, 27: 61.
  • 9Huang X, Wong MK, Zhao Q, et al. Soluble recombinant endostatin purified from Escherichia coli: antiangiogenic activity and antitumor effect[J]. Cancer Res, 2001, 61 : 478 - 481.
  • 10Schaffhauser B, Veikkola T, Strittmatter K, et al. Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice [J]. J Leukoc Biol, 2006, 80: 669- 676.

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部